文献速递皮肤肿瘤

表皮AMBRA1与loricrin表达可独立于Breslow厚度预测AJCC I期黑色素瘤预后

Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas.
PubMed 文献 · Br J Dermatol · 2019-06-19

本研究在76例AJCC I期黑色素瘤发现队列中评估瘤周表皮AMBRA1表达,并在218例验证队列和161例确认队列中分析AMLo(AMBRA1/loricrin)表达与最长12年临床结局的相关性。

要点

  • 瘤周表皮AMLo表达缺失可识别AJCC I期黑色素瘤高危亚组。
  • AMLo对DFS的预测独立于Breslow厚度。

核心结论

  • 原发AJCC I期黑色素瘤上方表皮AMLo表达缺失可独立于Breslow厚度识别高危肿瘤亚组。

研究设计与样本

  • 回顾性发现队列纳入76例AJCC I期黑色素瘤,评估瘤周AMBRA1表达。
  • 回顾性验证队列(n=218)和确认队列(n=161)共379例AJCC I期黑色素瘤,采用免疫组化方案半定量分析AMLo表达,随访至12年。

临床怎么用

  • 可将瘤周表皮AMBRA1/loricrin生物标志物表达纳入黑色素瘤诊疗指南,以促进AJCC I期患者更精准的个体化风险分层。
  • 风险分层有助于确定随访策略并指导诊断后检查(包括前哨淋巴结活检),最终改善疾病结局并合理化医疗成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The updated American Joint Committee on Cancer (AJCC) staging criteria for melanoma remain unable to identify high-risk stage I tumour subsets. OBJECTIVES: To determine the utility of epidermal autophagy and beclin 1 regulator 1 (AMBRA1)/loricrin (AMLo) expression as a prognostic biomarker for AJCC stage I cutaneous melanoma. METHODS: Peritumoral AMBRA1 expression was evaluated in a retrospective discovery cohort of 76 AJCC stage I melanomas. AMLo expression was correlated with clinical outcomes up to 12 years in two independent powered, retrospective validation and qualification cohorts comprising 379 AJCC stage I melanomas. RESULTS: Decreased AMBRA1 expression in the epidermis overlying primary melanomas in a discovery cohort of 76 AJCC stage I tumours was associated with a 7-year disease-free survival (DFS) rate of 81·5% vs. 100% survival with maintained AMBRA1 (P < 0·081). Following an immunohistochemistry protocol for semi-quantitative analysis of AMLo, analysis was undertaken in validation (n = 218) and qualification cohorts (n = 161) of AJCC stage I melanomas. Combined cohort analysis revealed a DFS rate of 98·3% in the AMLo low-risk group (n = 239) vs. 85·4% in the AMLo high-risk cohort (n = 140; P < 0·001). Subcohort multivariate analysis revealed that an AMLo hazard ratio (HR) of 4·04 [95% confidence interval (CI) 1·69-9·66; P = 0·002] is a stronger predictor of DFS than Breslow depth (HR 2·97, 95% CI 0·93-9·56; P = 0·068) in stage IB patients. CONCLUSIONS: Loss of AMLo expression in the epidermis overlying primary AJCC stage I melanomas identifies high-risk tumour subsets independently of Breslow depth. What's already known about this topic? There is an unmet clinical need for biomarkers of early-stage melanoma. Autophagy and beclin 1 regulator 1 (AMBRA1) is a proautophagy regulatory protein with known roles in cell proliferation and differentiation, and is a known tumour suppressor. Loricrin is a marker of epidermal terminal differentiation. What does this study add? AMBRA1 has a functional role in keratinocyte/epidermal proliferation and differentiation. The combined decrease/loss of peritumoral AMBRA1 and loricrin is associated with a significantly increased risk of metastatic spread in American Joint Committee on Cancer (AJCC) stage I tumours vs. melanomas, in which peritumoral AMBRA1 and loricrin are maintained, independently of Breslow depth. What is the translational message? The integration of peritumoral epidermal AMBRA1/loricrin biomarker expression into melanoma care guidelines will facilitate more accurate, personalized risk stratification for patients with AJCC stage I melanomas, thereby facilitating stratification for appropriate follow-up and informing postdiagnostic investigations, including sentinel lymph node biopsy, ultimately resulting in improved disease outcomes and rationalization of healthcare costs.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ellis R, Tang D, Nasr B, et al. Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas. Br J Dermatol. 2019. PMID: 31056744. doi:10.1111/bjd.18086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。